Kobayashi Pharmaceutical Co (TSE:4967) Debt-to-EBITDA : N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4967 Kobayashi Pharmaceutical Co Ltd TSE:4967
81 GF Score
Price 円5,680.00
GF Value 円4,818.55
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Kobayashi Pharmaceutical Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Kobayashi Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was 円271 Mil. Kobayashi Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was 円452 Mil. Kobayashi Pharmaceutical Co's annualized EBITDA for the quarter that ended in Jun. 2026 was 円0 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Kobayashi Pharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:

TSE:4967' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02   Med: 0.03   Max: 0.06
Current: 0.06

During the past 13 years, the highest Debt-to-EBITDA Ratio of Kobayashi Pharmaceutical Co was 0.06. The lowest was 0.02. And the median was 0.03.

TSE:4967's Debt-to-EBITDA is ranked better than
94.93% of 1559 companies
in the Consumer Packaged Goods industry
Industry Median: 2.12 vs TSE:4967: 0.06

Kobayashi Pharmaceutical Co  (TSE:4967) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Kobayashi Pharmaceutical Co Debt-to-EBITDA Related Terms


Kobayashi Pharmaceutical Co Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Kobayashi Pharmaceutical Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kobayashi Pharmaceutical Co Debt-to-EBITDA Chart

Kobayashi Pharmaceutical Co Annual Data
Trend Mar16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.02 0.03 0.04 0.05

Kobayashi Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.25 0.05 0.10 N/A

TSE:4967 vs PG, CL, KVUE: Debt-to-EBITDA Comparison

For the Household & Personal Products subindustry, Kobayashi Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kobayashi Pharmaceutical Co Debt-to-EBITDA vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Kobayashi Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Kobayashi Pharmaceutical Co's Debt-to-EBITDA falls into.


TSE:4967
81GF Score
Kobayashi Pharmaceutical Co Ltd TSE:4967
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kobayashi Pharmaceutical Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Kobayashi Pharmaceutical Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(319 + 359) / 12517
=0.05

Kobayashi Pharmaceutical Co's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is Kobayashi Pharmaceutical Co (TSE:4967) Overvalued in 2026?

Based on GuruFocus' analysis, Kobayashi Pharmaceutical Co stock appears to be overvalued. The current stock price of 円5,680.00 is trading 17.9% above its estimated GF Value™ of 円4,818.55. GuruFocus considers Kobayashi Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for TSE:4967:

  • Debt-to-EBITDA: N/A
  • GF Value™: 円4,818.55 vs. price of 円5,680.00 (17.9% above fair value)
  • GF Score™: 81/100 with 6 warning signs

No single metric tells the full story. See the TSE:4967 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Kobayashi Pharmaceutical Co Business Description

Other Exchanges KOY:Germany
Address 4-4-10 Doshomachi, KDX Kobayashi Doshomachi Building, Chuo-ku, Osaka, JPN, 541-0045
Kobayashi Pharmaceutical Co Ltd is engaged in the manufacture and sale of healthcare products, daily necessities, and body warmers. The company operates through two reportable segments: Domestic Business and International Business, which handle production and sales activities in Japan and overseas, respectively. The company's product portfolio includes disposable body warmers, cooling gel sheets, OTC pharmaceuticals, oral hygiene products, air fresheners, eyeglass wipes, and deodorizing/household sundries.
81GF Score

Get the complete analysis for TSE:4967

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円5,680.00
Price
円4,818.55
GF Value